


**CLAIMS****What is claimed is:**


1. A method for treating breast cancer and/or treating breast cancer metastasis in a subject in need of such treatment comprising administering to said subject an effective amount of *Crassocephalum rabens* extract and optionally a pharmaceutically acceptable carrier or excipient.
2. The method according to claim 1, wherein the *Crassocephalum rabens* extract is an alcohol extract.
3. The method according to claim 2, wherein the alcohol is C1 to C4 alcohol.
4. The method according to claim 1, wherein the *Crassocephalum rabens* extract comprises a compound represented by Formula I,  
 1,2-di-*O*- $\alpha$ -linolenoyl-3-*O*- $\beta$ -galactopyranosyl-*sn*-glycerol (dLGG),  
 1(2)-*O*- $\alpha$ -linolenoyl-2(1)-*O*- $\alpha$ -linoleoyl 3-*O*- $\beta$ -galactopyranosyl-*sn*-glycerol (18:3/18:2),  
 1(2)-*O*- $\alpha$ -linolenoyl-2(1)-*O*- $\alpha$ -palmitoyl 3-*O*- $\beta$ -galactopyranosyl-*sn*-glycerol (18:3/16:0),  
 1(2)-*O*- $\alpha$ -linolenoyl-2(1)-*O*- $\alpha$ -oleoyl 3-*O*- $\beta$ -galactopyranosyl-*sn*-glycerol (18:3/18:1) and  
 1,2-di-*O*- $\alpha$ -linolenoyl-3-*O*-(6-*O*- $\alpha$ -galactopyranosyl- $\beta$ -galactopyranosyl)-*sn*-glycerol (DGDG) ;



wherein of  $R_1$  and  $R_2$ , independently, is  $C(O)R_a$  in which  $R_a$  is  $C_{15-17}$  alkyl having 0 to 3 double bonds, and  $R_3$  is monogalactosyl or digalactosyl.

5. The method according to claim 1, wherein the breast cancer comprises breast cancer cells selected from the group consisting of ER+ breast cancer cells, Her2+ breast cancer cells and ER-, PR- and Her2- breast cancer cells.

6. The method according to claim 1, which is for inhibiting breast cancer cell proliferation, promoting apoptosis of breast cancer cells, suppressing tumor induced inflammation or metastasis-induced inflammation, decreasing expression levels of metastasis related proteins selected from the group consisting of Src, FAK, Rac 1, Cav-1, CYP2C19 and COX-2, or increasing survival rate of the subject.
7. The method according to claim 1, which is for treating breast cancer metastasis to the lung or liver.
8. The method according to claim 1, which further comprises administering to said subject with doxorubicin, epirubicin, bevacizumab, gemcitabine, 5-fluorouracil, capecitabine, cyclophosphamide, carboplatin, cisplatin, oxaliplatin, or vinblastine.
9. The method according to claim 8, which is further for attenuating the side effects of doxorubicin, epirubicin, bevacizumab, gemcitabine, 5-fluorouracil, capecitabine, cyclophosphamide, carboplatin, cisplatin, oxaliplatin, or vinblastine.
10. The method according to claim 9, wherein the side effects are selected from the group consisting of body weight loss, compromised immune response, cachexia, fatigue, cardiomyopathy, and COX-2 overexpression.
11. A method for treating breast cancer and/or treating breast cancer metastasis in a subject in need of such treatment comprising administering to said subject an effective amount of a compound represented by Formula I, 1,2-di-*O*- $\alpha$ -linolenoyl-3-*O*- $\beta$ -galactopyranosyl-*sn*-glycerol (dLGG), 1(2)-*O*- $\alpha$ -linolenoyl-2(1)-*O*- $\alpha$ -linoleoyl 3-*O*- $\beta$ -galactopyranosyl-*sn*-glycerol (18:3/18:2), 1(2)-*O*- $\alpha$ -linolenoyl-2(1)-*O*- $\alpha$ -palmitoyl 3-*O*- $\beta$ -galactopyranosyl-*sn*-glycerol (18:3/16:0), 1(2)-*O*- $\alpha$ -linolenoyl-2(1)-*O*- $\alpha$ -oleoyl 3-*O*- $\beta$ -galactopyranosyl-*sn*-glycerol (18:3/18:1), and 1,2-di-*O*- $\alpha$ -linolenoyl-3-*O*-(6-*O*- $\alpha$ -galactopyranosyl- $\beta$ -galactopyranosyl)-*sn*-glycerol (DGDG), or a pharmaceutically acceptable derivative thereof and optionally a pharmaceutically acceptable carrier or excipient;



wherein of  $R_1$  and  $R_2$ , independently, is  $C(O)R_a$  in which  $R_a$  is  $C_{15-17}$  alkyl having 0 to 3 double bonds, and  $R_3$  is monogalactosyl or digalactosyl.

12. The method according to claim 11, wherein the breast cancer comprises breast cancer cells selected from the group consisting of ER+ breast cancer cells, Her2+ breast cancer cells and ER-, PR- and Her2- breast cancer cells.
13. The method according to claim 11, which is for inhibiting breast cancer cell proliferation, promoting apoptosis of breast cancer cells, suppressing tumor induced inflammation or metastasis-induced inflammation, decreasing expression levels of metastasis related proteins selected from the group consisting of Src, FAK, Rac 1, Cav-1, CYP2C19 and COX-2, or increasing survival rate of the subject.
14. The method according to claim 11, which is for treating breast cancer metastasis to the lung or liver.
15. The method according to claim 11, which further comprises administering to said subject with doxorubicin, epirubicin, bevacizumab, gemcitabine, 5-fluorouracil, cyclophosphamide, carboplatin, cisplatin, oxaliplatin, paclitaxel, docetaxel, or vinblastine.
16. The method according to claim 15, which is further for attenuating the side effects of doxorubicin, epirubicin, bevacizumab, gemcitabine, 5-fluorouracil, capecitabine, cyclophosphamide, carboplatin, cisplatin, oxaliplatin, or vinblastine.
17. The method according to claim 16, wherein the side effects are selected from the group consisting of body weight loss, compromised immune response, cachexia, fatigue, cardiomyopathy, and COX-2 overexpression.